Live
- ‘Basti plan’ must be implemented: Ronald Rose
- Visakhapatnam: TDP Bheemili MLA says people in need of change
- Voting is not only right but also responsibility, says AP CEO
- ECI censures Minister Konda Surekha
- PM Modi must read Congress manifesto first
- DCA carries out series of raids, seizes drugs
- Eatala dares CM to implement farm loan waiver without selling lands
- Vijayawada: AAG Ponnavolu condemns Sharmila’s remarks
- Malla Reddy to join BJP?
- Hyderabad: Saviour of special needs kids
Dr Reddy’s FDA gets nod for psoriasis drug Impoyz
Dr Reddy’s Laboratories (DRL) has received first cycle new drug application (NDA) approval from the US Food and Drug Administration (USFDA) for its psoriasis treatment Impoyz cream.
Hyderabad: Dr Reddy’s Laboratories (DRL) has received first cycle new drug application (NDA) approval from the US Food and Drug Administration (USFDA) for its psoriasis treatment Impoyz cream. Dr Reddy's Laboratories in a release said that “Through its wholly-owned subsidiary Promius Pharma LLC, it has received its fifth consecutive, first-cycle NDA approval from the US health regulator for the Proprietary Products Group.”
“We’re looking forward to working with our partner, Encore Dermatology, to bring this novel treatment to providers and their patients,” Promius Pharma President and Senior Vice President, Proprietary Products Anil Namboodiripad said.
Robert Moccia, CEO of Encore Dermatology Inc, said: “Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialise a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne.” Impoyz, formerly referred to as DFD-06, had been recently licensed to Encore Dermatology Inc for the commercialisation of the product in the US.
